Bioadhesive controlled metronidazole release matrix based on chitosan and xanthan gum

Marine Drugs

Volumn 8, Issue 5, 2010, Pages 1716-1730

  Eftaiha, Ala'a F ^a   Qinna, Nidal ^a,b   Rashid, Iyad S ^a   Al Remawi, Mayyas M ^a   Al Shami, Munther R ^a   Arafat, Tawfiq A ^c   Badwan, Adnan A ^a  

^a JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

^b UNIVERSITY OF PETRA   (Jordan)

^c Jordan Center for Pharmaceutical Research Amman   (Jordan)

Author keywords

Bioadhesion; Bioavailability; Chitosan; Metronidazole; Xanthan gum

Indexed keywords

CHITOSAN; HYDROCHLORIC ACID; METRONIDAZOLE; PHOSPHATE; POLYMER; XANTHAN; BACTERIAL POLYSACCHARIDE; DELAYED RELEASE FORMULATION;

ADULT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG SYNTHESIS; DUODENUM MUCOSA; EX VIVO STUDY; EXTENDED RELEASE FORMULATION; HUMAN; HUMAN EXPERIMENT; HYDROGEL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE TRANSIT TIME; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NORMAL HUMAN; PH; SINGLE DRUG DOSE; SMALL INTESTINE MUCOSA; STOMACH MUCOSA; TIME TO MAXIMUM PLASMA CONCENTRATION; ADHESION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DUODENUM; SHEEP; STOMACH;

OVIS ARIES;

ADHESIVENESS; ANIMALS; BIOLOGICAL AVAILABILITY; CHITOSAN; DELAYED-ACTION PREPARATIONS; DUODENUM; HUMANS; METRONIDAZOLE; POLYMERS; POLYSACCHARIDES, BACTERIAL; SHEEP; STOMACH;

EID: 77952994816     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md8051716     Document Type: Article

References (38)

1. Dhopeshwarkar, V.; Zata, J. Evaluation of xanthan gum in the preparation of sustained release matrix tablets. Drug Dev. Ind. Pharm. 1993, 19, 999-1017.
2. Siepmann, J.; Peppas, N.A. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv. Drug Deliv. Rev. 2001, 48, 139-157.
3. Davaran, S.; Rashidi, M.R.; Khani, A. Synthesis of chemically cross-linked hydroxypropyl methyl cellulose hydrogels and their application in controlled release of 5-amino salicylic acid. Drug Dev. Ind. Pharm. 2007, 33, 881-887.
4. Paul, W.; Sharma, C.P. Chitosan, A drug carrier for the 21st century. STP Pharma Sci. 2000, 10, 5-22.
5. Lindner, W.D.; Lippold, B.C. Drug release from hydrocolloid embeddings with high or low susceptibility to hydrodynamic stress. Pharm. Res. 1995, 12, 1781-1785.
6. Rajabi-Siahboomi, A.R.; Bowtell, R.W.; Mansfield, P.; Davies, M.C. Structure and behavior in hydrophilic matrix sustained release dosage forms: 4. Studies of water mobility and diffusion coefficients in the gel layer of hpmc tablets using NMR imaging. Pharm. Res. 1996, 13, 376-380.
7. Am Ende, M.; Bell, L.; Peppas, N.; Massimo, G.; Colombo, P. Measurement of the swelling force in ionic polymeric networks: II. Swelling force and disintegration of controlled release dosage formulations using ph-sensitive components. Int. J. Pharm. 1995, 120, 33-40.
8. Harland, R.; Dubernet, C.; Benoît, J.; Peppas, N. A model of dissolution-controlled, diffusional drug release from non-swellable polymeric microspheres. J. Control. Rel. 1988, 7, 207-215.
9. Sandolo, C.; Coviello, T.; Matricardi, P.; Alhaique, F. Characterization of polysaccharide hydrogels for modified drug delivery. Eur. Biophys. J. 2007, 36, 693-700. (Pubitemid 350092516)
10. Staniforth, J.N.; Baichwal, A.R. Timerx: novel polysaccharide composites for controlled/programmed release of drugs in the gastrointestinal tract. Expert Opin. Drug Deliv. 2005, 2, 587-595.
11. Baichwal, A.R. Controlled release oxybutynin formulations. US Patent 5399359, 1995.
12. Felt, O.; Buri, P.; Gurny, R. Chitosan: A unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 1998, 24, 979-993.
13. Dodane, V.; Vilivalam, V. Pharmaceutical applications of chitosan. Pharm. Sci. Technol. Today. 1998, 1, 246-253.
14. Muzzarelli, R.A.A. Enhanced biochemical efficacy of oligomeric and partially depolymerized chitosans. In Chitosan: Manufacture, Properties and Usages; Columbus, F., Ed.; Nova Publishers: Hauppauge, NY, USA, 2010.
15. Talukdar, M.M.; Vinckier, I.; Moldenaers, P.; Kinget, R. Rheological characterization of xanthan gum and hydroxypropylmethyl cellulose with respect to controlled-release drug delivery. J. Pharm. Sci. 1996, 85, 537-540.
16. El Gazayerly, O.N. Release of Pentoxifylline from Xanthan Gum Matrix Tablets. Drug Dev. Ind. Pharm. 2003, 29, 241-246.
17. Fukuda, M.; Peppas, N.A.; Mcginity, J.W. Properties Of sustained release hot-melt extruded tablets containing chitosan and xanthan gum. Int. J. Pharm. 2006, 310, 90-100.
18. Dumtriu, S.; Chornet, E; Vidal, P. Poly-ionic insoluble hydrogels comprising xanthan gum and chitosan. US Patent 5620706, 1997.
19. Moes, A.J. Gastroretentive dosage forms. Crit. Rev. Ther. Drug Carrier Sys. 1993, 10, 143-195.
20. Miyazaki, S.; Nakayama, A.; Oda, M.; Takada, M.; Attwood, D. Drug release from oral mucosal adhesive tablets of chitosan and sodium alginate. Int. J. Pharm. 1995, 118, 257-263.
21. Miyazaki, S.; Nakayama, A.; Oda, M.; Takada, M.; Attwood, D. Chitosan and alginate based bioadhesive tablets for intraoral drug delivery. Biol. Pharm. Bull. 1994, 17, 745-747.
22. Nakamura, F.; Ohta, R.; Machida, Y.; Nagai, T. In vitro and in vivo nasal mucoadhesion of some water-soluble polymers. Int. J. Pharm. 1996, 134, 173-181.
23. Badwan, A.A; Al-Remawi, M. Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate. US Patent 2008206334, 2008.
24. Badwan, A.A.; Al-Remawi, M.; Salem, M. Universal controlled-release composition comprising chitosan. European Patent EP1512394, 2008.
25. Eftaiha, A.F.; El-Barghouthi, M.I.; Rashid, I.S.; Al-Remawi, M.M.; Saleh, A.I.; Badwan, A.A. Compressibility and compactibility studies of chitosan, xanthan gum, and their mixtures. J. Mater. Sci. 2009, 44, 1054-1062.
26. Andrews, G.P.; Laverty, T.P.; Jones, D.S. Mucoadhesive Polymeric Platforms For Controlled Drug Delivery. Eur. J. Pharm. Biopharm. 2009, 71, 505-518.
27. Idkaidek, N.M.; Najib, N.M. Enhancement of oral absorption of metronidazole suspension in humans. Eur. J. Pharm. Biopharm. 2000, 50, 213-216.
28. Goodwin, A.; Kersulyte, D.; Sisson, G.; Veldhuyzen van Zanten, S.J.; Berg, D.E.; Hoffman, P.S. Metronidazole resistance in helicobacter pylori is due to null mutations in a gene (rdxa) that encodes an oxygen-insensitive nadph nitroreductase. Mol. Microbiol. 1998, 28, 383-393.
29. Bulck, K.; Decostere, A.; Gruntar, I.; Baele, M.; Krt, B.; Ducatelle R.; Haesebrouck, F. In vitro antimicrobial susceptibility testing of helicobacter felis, H. Bizzozeronii, H. Salomoni. Antimicrob Agents Chemother. 2005, 49, 2997-3000. (Pubitemid 40917625)
30. Dagana, R.; Klugmanb, K.P.; Craigc, W.A.; Baquerod, F. Evidence To support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 2001, 47, 129-140.
31. Ball, P., Baquero, F., Cars, O.; File, T.; Garau, J.; Klugman, K.; Low, D.E.; Rubinstein, E.; Wise, R. Antibiotic therapy of community respiratory tract infections: Strategies for optimal outcomes and minimized resistance emergence. the consensus group on resistance and prescribing in respiratory tract infection. J. Antimicrob. Chemother. 2002, 49, 31-40.
32. Jacobs, M.R. How can we predict bacterial eradication? Int. J. Inf. Dis. 2003, 7, 13-20.
33. Craig, W.A. Antimicrobial resistance issues of the future. Diag. Micro. Inf. Dis. 1996, 25, 213-217.
34. Craig, W.A. Pharmacokinetic/Pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin. Inf. Dis. 1998, 26, 1-12.
35. Garau, J. Why do we need to eradicate pathogens in respiratory tract infection? Int. J. Inf. Dis. 2003, 7, 5-12.
36. Lonks, J.R.; Garau, J.; Gomez, L.; Xercavins, M.; Ochoa de Echagüen, A.; Gareen, I.F.; Reiss, P.T.; Medeiros, A.A. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin resistant streptococcus pneumoniae. Clin. Inf. Dis. 2002, 35, 556-564.
37. US Food and Drug Administration. Code of Federal Register; 1995; Volume 60, pp. 61638-61642.
38. Parodi, B.; Russo, E.; Caviglioli, G.; Cafaggi, S. Development and characterization of a buccoadhesive dosage form of oxycodone hydrochloride. Drug Dev. Ind. Pharm. 1996, 22, 445-450.